International reference: 1 US FDA recall for this ingredient
Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared. (strontium)
US-market enforcement records (OpenFDA), shown for reference - not specific to this product in Kenya.
What it does
Ranelate is a medication used to help strengthen bones and reduce the risk of fractures.
Commonly used for: osteoporosis (weak bones)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 21:10:00 · updated 2026-07-20 08:53:07
Drug Interactions
2Pharmacodynamic Warnings
Strontium appears in TABLE 5: Drugs that cause thromboembolism
Severe (2)
Quinolones - decreases absorption
Strontiumispredictedtodecreasetheabsorptionof quinolones.Avoid.oTheoretical
Tetracyclines - decreases absorption
Strontium is predicted to decrease the absorption of tetracyclines. Avoid. Theoretical Sucralfate
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About ranelate
Ranelate is a medication used to help strengthen bones and reduce the risk of fractures.
What it treats
- osteoporosis (weak bones)
How it works
It helps to build bone density and reduces the likelihood of bone fractures.
Who it's for
This medication is typically prescribed for postmenopausal women or individuals at high risk for bone fractures.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About strontium
Strontium is a supplement used to support bone health and may be particularly helpful in conditions related to bone density.
What it treats
- bone health
- osteoporosis
How it works
Strontium helps to strengthen bones and may reduce the risk of fractures.
Who it's for
People at risk of weak bones, such as those with osteoporosis.
Cautions
- • Avoid if you are taking medications that can cause blood clots.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: ranelate
BNF-referencedRanelate is a medication used primarily in the treatment of osteoporosis. It is a calcium salt of ranelic acid and serves as an anti-osteoporotic agent. Ranelate helps to reduce the risk of vertebral and hip fractures in postmenopausal women and is also indicated for use in men at risk of osteoporosis. Its ability to improve bone mineral density and reduce fracture risk makes it a valuable option in osteoporosis management.
Indications
- Osteoporosis in postmenopausal women
- Osteoporosis in men at risk
- Prevention of vertebral and hip fractures
Dosage
Adults: The usual adult dose is 2 g of ranelate taken orally once a day, preferably at the same time each day.
Mechanism of action
Ranelate acts through a dual mechanism: it promotes bone formation and reduces bone resorption. The drug enhances osteoblastic activity, which is responsible for bone formation, while simultaneously inhibiting osteoclastic activity, which is involved in bone resorption, thereby contributing to an overall increase in bone mass.
Pharmacodynamics
The pharmacodynamic effects of ranelate include increased bone mineral density (BMD) and a decrease in the incidence of fractures in patients with osteoporosis. Ranelate has a unique profile that distinguishes it from other anti-osteoporotic therapies by promoting bone formation rather than solely inhibiting resorption, which is the mechanism of action of many other osteoporosis treatments.
Pharmacokinetics
Ranelate is administered orally and is poorly absorbed from the gastrointestinal tract. It has a bioavailability of approximately 1%. The drug is metabolized in the liver, and its elimination half-life is approximately 4 to 6 hours. Renal clearance is a significant route of elimination, thus dosage adjustments may be needed in patients with renal impairment. Due to its calcium content, it is recommended to monitor calcium levels in patients during treatment.
Contra-indications
- Hypersensitivity to ranelate or any of its components
- Patients with a history of venous thromboembolism
- Patients with severe renal impairment
- Pregnancy and breastfeeding
Adverse effects
- Gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain
- Skin reactions including rash and pruritus
- Headache
- Dizziness
- Increased risk of venous thromboembolism
Interactions
- May interact with other medications that affect bone metabolism
- Caution when combined with anticoagulants due to the increased risk of bleeding
Precautions
- Use with caution in patients with a history of cardiovascular disease
- Monitor renal function regularly during treatment
- Ensure adequate calcium and vitamin D intake during therapy
Pregnancy
Ranelate is contraindicated in pregnancy due to potential risks to the fetus.
Breast-feeding
Ranelate is contraindicated in breastfeeding. It is not known whether ranelate is excreted in human milk.
Storage
Store at room temperature, away from moisture and heat. Keep out of reach of children.
Formulations
- Oral powder for suspension
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: strontium
BNF-referencedStrontium is a chemical element, classified as an alkaline earth metal, with the symbol Sr and atomic number 38. It is primarily known for its role in bone health, often analyzed in the context of strontium ranelate, a compound used in the treatment of osteoporosis. Strontium can influence bone metabolism and density, making it a subject of interest in the management of skeletal disorders.
Indications
- Osteoporosis
- Bone density enhancement
- Management of bone health
Dosage
Children: Refer to the BNF for Children for specific dosing information.
Adults: Refer to the BNF for specific dosing information.
Mechanism of action
Strontium acts by promoting bone formation and inhibiting bone resorption. It mimics calcium in the body and is incorporated into the bone matrix, thereby enhancing bone strength and density. The precise mechanisms include modulation of osteoblast and osteoclast activity, leading to an overall increase in bone mineral density.
Pharmacodynamics
Strontium influences the balance between bone formation and resorption. It stimulates the proliferation and activity of osteoblasts (bone-forming cells) while reducing the activity of osteoclasts (bone-resorbing cells). This dual action helps in restoring the balance in bone remodeling, which is often disrupted in conditions such as osteoporosis.
Pharmacokinetics
After administration, strontium is absorbed in the gastrointestinal tract, although its absorption can be significantly affected by the presence of other compounds. It distributes into the bone, where it remains for extended periods. The biological half-life of strontium in bone can be several years, contributing to its long-term effects on bone density. Excretion occurs primarily via the kidneys.
Interactions
- strontium+quinolones: Severe (decreases absorption)
- strontium+tetracyclines: Severe (decreases absorption)
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: ranelate
PubChem CID 3052774Molecular formula: C12H10N2O8S
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
Molecular reference: strontium
PubChem CID 5359327Molecular formula: Sr
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.